Navigation Links
Sorrento Therapeutics, Inc. and QuikByte Software, Inc. Complete Merger
Date:9/18/2009

able exemptions from registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.

About Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc., a wholly-owned subsidiary of QuikByte Software, Inc., is a development-stage biopharmaceutical company focused on applying its proprietary technology platform for the discovery and development of human therapeutic antibodies for the treatment of a variety of disease conditions, including cancer, inflammation, metabolic disease and infectious disease. The Company seeks to construct an antibody library containing fully human antibodies and designed to facilitate the rapid identification and isolation of highly specific, antibody therapeutic product candidates that are fully human and that bind to disease targets appropriate for antibody therapy.

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects, the merger and the other transactions contemplated by the merger agreement. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to, the possibility that some or all of the pending matters and transactions considered by QuikByte may not proceed as contemplated, and by all
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
2. Cell Therapeutics, Inc. (CTI) Advances Pixantrone Filing Process in Europe; Submits Pediatric Investigation Plan (PIP)
3. Cell Therapeutics, Inc. (CTI) to Present at BioCenturys NewsMakers in the Biotech Industry Conference
4. Oxygen Biotherapeutics, Inc. Seeks Shareholder Approval for Reverse Stock Split
5. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw Healthcare Conference
6. Oxygen Biotherapeutics, Inc. to Present at Investment Conferences in New York and Zurich
7. Cell Therapeutics, Inc. Announces Closing of Registered Offering of $30 Million of Preferred Stock and Warrants
8. Cell Therapeutics, Inc. Announces Institutional Investor Purchases $30 Million of Preferred Stock and Warrants
9. Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009
10. Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure
11. Cell Therapeutics, Inc. Announces Exercise of Overallotment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... MONMOUTH JUNCTION, N.J., March 31, 2015 ... immunotherapy company using blood purification to treat critically-ill ... provides an operational summary and reports financial results ... 2014 CytoSorb® product revenues were ... 281%, compared to 2013 CytoSorb® revenues of $0.8M ...
(Date:3/31/2015)... 2015 Materials in Society Lecture ... June 30 2015   Elsevier , a ... services and publishing home of Materials Today , announced ... Materials in Society  Lecture Series . ... th International Conference on Materials for Advanced Technologies (ICMAT) ...
(Date:3/31/2015)... March 31, 2015   Mapi expands ... Medical Affairs and global Risk Management strength with ... previously announced acquisition . ... by a global team that includes physicians, pharmacists, ... of experience in navigating complex safety requirements throughout ...
(Date:3/31/2015)... This June 13th, a distinguished group of ... International Medical Schools will come together in Santa Monica, ... of stem cell therapy in treatments and cures for ... by the Ocular Research Symposia Foundation, Inc. ... meetings of top experts in the field of eye ...
Breaking Biology Technology:CytoSorbents Reports Record 2014 Revenue 2CytoSorbents Reports Record 2014 Revenue 3CytoSorbents Reports Record 2014 Revenue 4CytoSorbents Reports Record 2014 Revenue 5CytoSorbents Reports Record 2014 Revenue 6CytoSorbents Reports Record 2014 Revenue 7CytoSorbents Reports Record 2014 Revenue 8CytoSorbents Reports Record 2014 Revenue 9CytoSorbents Reports Record 2014 Revenue 10CytoSorbents Reports Record 2014 Revenue 11Elsevier Materials Science Council Introduces the Materials in Society Lecture Series at the International Conference on Materials for Advanced Technologies (ICMAT) 2Elsevier Materials Science Council Introduces the Materials in Society Lecture Series at the International Conference on Materials for Advanced Technologies (ICMAT) 3Mapi expands Pharmacovigilance and Risk Management capabilities 2Mapi expands Pharmacovigilance and Risk Management capabilities 3Sight Restoration Through Stem Cell Therapy - Subject of June Symposium of Experts 2
... carbon nanotubes more than doubles the growth rate of ... everything from lifesaving medications to sweeteners to dyes and ... to show that carbon nanotubes boost plant cell division ... . Mariya V. Khodakovskaya and colleagues explain that ...
... Ga., April 4, 2012  MiMedx Group, Inc. (OTCBB: MDXG), ... regenerative biomaterials and bioimplants processed from human amniotic membrane, ... revenue goal for the first quarter of 2012. The ... $3.6 million. The Company also reported ...
... SETAUKET, N.Y., April 4, 2012 Lixte Biotechnology Holdings, ... the United States Patent and Trademark Office for its ... homologs. Dr. John Kovach, founder and president ... certain types of skin lymphomas and many other HDACi ...
Cached Biology Technology:MiMedx Exceeds Revenue Goal for First Quarter of 2012 2Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor 2Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor 3
(Date:3/20/2015)... Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the addition ... report to their offering. This report analyzes ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided for ...
(Date:3/18/2015)... SPRINGS, Florida , March 18, 2015 ... well as businesses, new revolutionary smart wallets and apps continue ... pace.  Companies currently entrenched in the mobile payment industry in ... Alibaba Group Holding Ltd. (NYSE: BABA ), Apple ... GOOG ) and Facebook Inc. (NASDAQ: FB ...
(Date:3/17/2015)... , March 17, 2015 Emotient, ... analytics software, today announced general availability of ... service for the analysis of facial expressions. The ... advertising, media content, products and services. It delivers ... engagement and sentiment - as derived from facial ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... between a wasp species and a newly discovered ... on how bacteria can be successfully utilized by ... In the new work, researchers show that a ... bacteria in unique structures within its antennae and ...
... a special protein found only in germ-line cells results ... a new study from researchers at the University of ... Human Reproduction in Penn's Center for Research in Reproduction ... point the way to a new type of contraceptive ...
... indoctrinated into believing that our senses, thoughts, feelings ... of brain cells, or neurons, each responsible for ... Either neurons release a neurotransmitter that excites a ... enhancing brain activity, or they dispatch a signal ...
Cached Biology News:Symbiotic bacteria protect hunting wasps from fungal infestation 2Of mice and men's (and women's) contraceptives 2Researchers make surprise discovery that some neurons can transmit three signals at once 2Researchers make surprise discovery that some neurons can transmit three signals at once 3
... dye terminators, template DNA, primers, salts or ... products have proved critical for both standard ... to work with dye terminator cycle sequencing ... The unique uniformity of the magnetic paeticles ...
Enodgenous alkaline phosphotase inhibitor. Levamisole solution is supplied in concentrated form (20x). The final concentration of levamisole in the substrate solution will be 1 mM....
uncoupling protein 2 (mitochondrial, proton carrier), mRNA (cDNA clone MGC:19567 IMAGE:4335185), complete cds...
Catch and Release® v2.0 Reversible Immunoprecipitation System...
Biology Products: